アブストラクト
Japanese
| Title | 日本の進行・再発食道がん二次治療におけるニボルマブの費用対効果 |
|---|---|
| Subtitle | 一般論文 |
| Authors | 近藤有, 榊原崇芳, 加藤潤, 渡邊雅史, 西村栄輝, 實安健市, 下野大貴, 間瀬悟, 三宅芳男 |
| Authors (kana) | |
| Organization | JA愛知厚生連豊田厚生病院薬剤部 |
| Journal | 医療薬学 |
| Volume | 46 |
| Number | 5 |
| Page | 239-248 |
| Year/Month | 2020 / 5 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」 日本の国民医療費は高齢化および高額な医薬品・医療技術の登場により増加を続けており, 2017年度の国民医療費は43兆円に達した(https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/17/dl/data.pdf, 2019年9月26日). 次々に登場する高額な医薬品・医療技術が日本の財政を圧迫することが懸念されており, 近年ではChimeric antigen receptor T細胞治療に使用される再生医療等製品であるキムリア(R)(ノバルティスファーマ(株), 東京)の患者1人当たりの治療費に3千万円を超える価格がつけられ, 大きな注目を集めた. 医薬品の薬価は中央社会保険医療協議会(中医協)で決定されるが, 医薬品・医療技術の価格を適切に評価することを目的に, 2012年に中医協に費用対効果評価専門部会が設置され, 薬価の決定に費用対効果を利用する議論が始まった. その後, 一部の医薬品・医療機器を対象として費用対効果の試行的導入が開始され, 2019年に本格的導入が始まっている. |
| Practice | 薬学 |
| Keywords | nivolumab, cost-effectiveness, esophageal cancer, docetaxel, incremental cost-effectiveness ratio |
English
| Title | Cost-Effectiveness of Nivolumab in Patients with Advanced or Recurrent Esophageal Cancer Receiving Second-Line Treatment in Japan |
|---|---|
| Subtitle | Regular Articles |
| Authors | Yu Kondo, Takayoshi Sakakibara, Jun Kato, Masashi Watanabe, Shigeki Nishimura, Kenichi Saneyasu, Daiki Shimono, Satoru Mase, Yoshio Miyake |
| Authors (kana) | |
| Organization | Department of Pharmacy, Toyota Kosei Hospital |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 46 |
| Number | 5 |
| Page | 239-248 |
| Year/Month | 2020 / 5 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | We developed a Markov model to evaluate the cost-effectiveness of nivolumab in patients with advanced or recurrent esophageal cancer receiving second-line treatment in Japan. We assessed an incremental cost-effective ratio (ICER) for nivolumab versus docetaxel from the health insurers' perspective. A threshold ICER was set at 7.5 million JPY. The ICER was calculated to be 12.45 million JPY per quality-adjusted life year, which was above the threshold. In a one-way sensitivity analysis, the results were most sensitive to the utility scores for nivolumab. If the cost of nivolumab per 240 mg could be reduced below 282,817 JPY or nivolumab could prolong the overall survival up to 4.1 months, the ICER fell below the threshold. The probabilistic sensitivity analysis revealed a 17.6% probability that nivolumab was cost-effective as compared to docetaxel. Our study suggests that nivolumab is not cost-effective in patients with advanced or recurrent esophageal cancer receiving second-line treatment as of this moment. Therefore, for future study, it is advisable to review drug prices and select patients who are expected to have high therapeutic effects. |
| Practice | Pharmaceutical sciences |
| Keywords | nivolumab, cost-effectiveness, esophageal cancer, docetaxel, incremental cost-effectiveness ratio |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y, Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 2019, 20, 1506-1517.
- 2) 国立がん研究センター内科レジデント編, "がん診療レジデントマニュアル", 第7版, 医学書院, 東京, 2016, pp110-118.
- 3) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR, Revised equations for estimated GFR from serum creatinine in Japan, Am J Kidney Dis, 2009, 53, 982-992.
- 4) Beck JR, Pauker SG, The Markov process in medical prognosis, Med Decis Making, 1983, 3, 419-458.
- 5) Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research, A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing, J Thorac Oncol, 2016, 11, 1846-1855.
残りの12件を表示する
- 6) Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA, Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes, J Med Econ, 2016, 19, 630-644.
- 7) Verma V, Sprave T, Haque W, Simone CB 2nd, Chang JY, Welsh JW, Thomas CR Jr, A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors, J Immunother Cancer, 2018, 6, 128. doi: 10.1186/s40425-018-0442-7.
- 8) Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, Arakawa I, Saito H, Inoue T, A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan, J Gastrointest Cancer, 2017, 48, 326-332.
- 9) Liu Q, Zeng H, Xia R, Chen G, Liu S, Zhang Z, Liu Y, Guo G, Song G, Zhu Y, Wu X, Song B, Liao X, Chen Y, Wei W, Chen W, Zhuang G, Health-related quality of life of esophageal cancer patients in daily life after treatment: A multicenter cross-sectional study in China, Cancer Med, 2018, 7, 5803-5811.
- 10) "薬価基準点数早見表", 令和元年10月版, 社会保険研究所, 東京, 2019, pp448-517.
- 11) Morishima T, Lee J, Otsubo T, Imanaka Y, Association of healthcare expenditures with aggressive versus palliative care for cancer patients at the end of life: a cross-sectional study using claims data in Japan, Int J Qual Health Care, 2014, 26, 79-86.
- 12) 池田俊也, 白岩健, 五十嵐中, 能登真一, 福田 敬, 齋藤信也, 下妻晃二郎, 日本語版EQ-5D-5Lにおけるスコアリング法の開発, 保険医療科学, 2015, 64, 47-55.
- 13) Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, Li Q, Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer, Lung Cancer, 2019, 130, 1-4.
- 14) 近藤有, 榊原崇芳, 古田美里, 平岩いずみ, 加藤潤, 加藤亜季, 平岩あずさ, カバジタキセル療法を受ける前立腺がん患者におけるペグフィルグラスチムの費用対効果, 日本病院薬剤師会雑誌, 2020, 56, 71-78.
- 15) 医学通信社編集部,"DPC点数早見表:診断群分類樹系図と包括点数・対象疾患一覧", 2018年4月版, 医学通信社, 東京, 2018, pp306-317.
- 16) 杉本智哉, 近藤有, 一木万奈美, 荒川裕貴, 間瀬広樹, 牛膓沙織, 佐久間昌基, 小山佐知子, 大島有美子, 宮崎雅之, 築山郁人, 佐藤由美子, 久田達也, 板倉由縁, 山田清文, 非ホジキンリンパ腫患者に対するCHOP療法に伴う発熱性好中球減少症の1次予防におけるペグフィルグラスチムの費用対効果, 医療薬学, 2018, 44, 441-448.
- 17) Everest L, Shah M, Chan KKW, Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale, JAMA Netw Open, 2019, 2, e196803. doi: 10.1001/jamanetworkopen.2019.6803.
